HighTower Advisors LLC Boosts Holdings in argenx SE (NASDAQ:ARGX)

HighTower Advisors LLC raised its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 128.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,677 shares of the company's stock after acquiring an additional 6,006 shares during the quarter. HighTower Advisors LLC's holdings in argenx were worth $6,566,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ARGX. Stifel Financial Corp increased its holdings in shares of argenx by 15.3% in the third quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock valued at $4,788,000 after purchasing an additional 1,170 shares during the last quarter. FMR LLC increased its stake in shares of argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after acquiring an additional 1,265,486 shares during the last quarter. Stephens Inc. AR purchased a new position in shares of argenx during the 4th quarter worth $310,000. Ritholtz Wealth Management boosted its position in shares of argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after acquiring an additional 414 shares during the last quarter. Finally, Westfield Capital Management Co. LP purchased a new stake in shares of argenx in the third quarter valued at about $571,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

Wall Street Analyst Weigh In

ARGX has been the topic of several recent analyst reports. Evercore ISI boosted their target price on shares of argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. HC Wainwright increased their price objective on argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Robert W. Baird lifted their target price on argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a research report on Tuesday, March 4th. Piper Sandler increased their price target on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a report on Tuesday, January 7th. Finally, Oppenheimer boosted their price objective on shares of argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $687.00.

Remove Ads

argenx Stock Up 1.4 %

NASDAQ ARGX traded up $8.79 on Wednesday, hitting $619.97. 377,277 shares of the stock were exchanged, compared to its average volume of 285,752. argenx SE has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The company has a 50-day moving average price of $636.24 and a 200-day moving average price of $598.37. The company has a market cap of $37.67 billion, a PE ratio of -704.51 and a beta of 0.59.

argenx (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities research analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.